Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
|Articles|February 15, 2002
- BioPharm International-02-01-2002
- Volume 15
- Issue 2
Outsourcing Outlook: Reaping the Benefits of E-Procurement
Author(s)Jim Miller, Heather B. Hayes
By Heather B. Hayes and Jim Miller, PharmSource Information Services, Inc., pp. 60-62. Not just a quick fix, e-procurement requires a thoughtful and thorough approach to produce the most rewards.
Advertisement
Articles in this issue
over 24 years ago
The Immunogenicity of Therapeutic Proteinsover 24 years ago
Inside Washington: Costs and Controls Challenge Manufacturersover 24 years ago
21 CFR Part 11: (Un)Expected Added ValueAdvertisement
Related to this article
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
At AAPS PharmSci 360, Thermo Fisher Scientific scientists described how predictive modeling guides technology selection for poorly soluble drugs, and outlined plans to bring solvent-free KinetiSol technology to commercial scale in 2027.
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
2
Fresenius and WuXi Biologics Sign Exclusive Agreement Covering Up to 37 Biosimilar Candidates
3
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
4
FDA Accepts uniQure’s Huntington’s Disease Gene Therapy BLA for Priority Review
5